SanBio Company Limited
【SanBio】Regenerative Medicine Drug Approval and Research & Development Progress｜June 2026
SanBio recorded research and development expenses of 680 million yen in the first quarter of the fiscal year ending January 2027, with an operating loss of 953 million yen and a net loss of 836 million yen. The company is advancing approvals for Aducor® and global expansion efforts.
Key Figures
- Net assets: 12,677 million yen (decreased by 926 million yen from the previous period end)
- Net loss attributable to owners of the parent: 836 million yen
- Research and Development expenses: 680 million yen
AI要約
Performance Overview
In the first quarter of the fiscal year ending January 2027, SanBio recorded research and development expenses of 680 million yen, an operating loss of 953 million yen, and a net loss of 836 million yen. The main factors include costs related to the approvals and conditional changes for Aducor®. Foreign exchange gains of 177 million yen reduced the ordinary loss to 779 million yen. The company is progressing with global expansion and clinical trial preparations, and expectations for future growth are high.
Financial Condition and Outlook
Total assets stand at 14,517 million yen, and net assets are 12,677 million yen, reflecting a decrease of 926 million yen from the previous period end. While current assets decreased, fixed assets increased. Liabilities rose to 2,016 million yen, and the equity ratio is 85.5%. Based on ongoing global expansion and clinical trials, the company anticipates medium- to long-term growth.
SanBio Co., Ltd.
Company overview · Stock price · Financial data · All IR
